Also known as: adamantinomatous craniopharyngioma, ordinary craniopharyngioma, papillary craniopharyngioma, Rathke pouch tumor, hypophyseal duct tumor, adamantinoma
What is a craniopharyngioma?
A craniopharyngioma is a non-cancerous brain tumor that develops from cells present during early brain development, and in childhood frequently presents between the ages of 5-14 years. It causes problems because it can grow and press on other parts of the brain (or glands near it) which are involved with sight and hormone production.
What causes craniopharyngioma?
At present while it appears that some chromosomal or genetic abnormalities have been described associated with these tumors, no clear cause has been identified.
What are the symptoms of craniopharyngioma?
Symptoms may include headache, vomiting, vision loss, symptoms of growth hormone and other endocrine gland deficiencies, seizures, mental changes (and other symptoms from brain involvement) and a presentation called "diencephalic syndrome" (which your pediatrician will need to outline for you).
What are craniopharyngioma care options?
Medical care involves managing the hormone problems with hormone replacement therapies; tumor control with chemotherapy (and other medical agents); and radiation. Surgery
to remove the tumor (with or without other therapies) is common though difficult.
Reviewed by: Jack Wolfsdorf, MD, FAAP
This page was last updated on: 5/23/2018 10:34:57 AM
This class is offered to parents and caregivers of children diagnosed with Autism Spectrum Disorders.
Learn more and register
Camp U.O.T.S. is an annual weeklong, overnight camp for children with cancer and blood disorders who are treated at Nicklaus Children’s Hospital.
Learn more and register
What was supposed to be a fun day for Frankie and his sister with their uncle quickly took an unexpected and tragic turn. Frankie was kicked in the head by a horse at the ranch they were visiting, and he suffered a traumatic brain injury.
From the Newsdesk
This conference is designed to provide individuals with Beckwith-Wiedemann Syndrome (BWS) and their family’s up-to-date information about the possible aspects of BWS and their management.
Grant is the first pediatric patient in South Florida to utilize the SenTiva VNS device, which is currently the smallest and lightest responsive therapy for epilepsy available on the market. The device, used in combination with epilepsy medications, has been shown to be effective in reducing seizure frequency and duration.